FUJIFILM IRVINE SCIENTIFIC TO SELL FUJIFILM CELLULAR DYNAMICS iCELL PRODUCTS
FUJIFILM Irvine Scientific creates the FUJIFILM “Discovery Research” organization to enable speedy, efficient delivery of FUJIFILM Cellular Dynamics iPSC-derived products through their worldwide distribution channels
March 31, 2020
Madison, Wis./ Irvine, Calif.— FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, and FUJIFILM Irvine Scientific, Inc., a leader in cell culture media, announced that beginning April 1, 2020 iCell® products will be sold by the FUJIFILM “Discovery Research” organization (part of FUJIFILM Irvine Scientific). FCDI will continue to lead product innovation, development and manufacture of all iCell products as well as provide the same high-quality logistics and technical support its customers have come to expect.
“At Fujifilm we are dedicated to helping customers accelerate their innovation and discoveries to advance research that can result in drug discovery and development,” said Takeshi Yamamoto, CEO, FUJIFILM Cellular Dynamics, Inc. “By joining forces with FUJIFILM Irvine Scientific to bring our iCell products to customers, we can now leverage synergies and strengths to benefit our partners and ultimately, drive even greater progress in the field.”
Founded in 1970, FUJIFILM Irvine Scientific is a leading developer and manufacturer of cell culture media for biopharmaceuticals, cell and gene therapy, regenerative medicine and reproductive medicine. With a global network of sales and support operations across the United States, European Union, and Asia, FUJIFILM Irvine Scientific is well-positioned to ensure speedy, efficient distribution of FCDI’s products and better serve customers’ needs.
Over the years, FCDI has provided high quality human iPSCs to its partners engaged in drug discovery research to evaluate the safety and efficacy of drug candidates, offering researchers more relevant human biology than the traditional animal models used in preclinical trials. FCDI’s leadership in this field has resulted in over 16 iPSC-derived cell types including neural cells, cardiac cells, and more, and thousands of donor-based disease lines.
While working with FUJIFILM Irvine Scientific’s commercial organization is the first step, the two Fujifilm Group companies will also work together on introducing exciting new joint product kits in the future.
“Fujifilm’s expertise in the life sciences supports drug development from early phase research through to commercialization,” said Yutaka Yamaguchi, CEO, FUJIFILM Irvine Scientific. “Fujifilm Group’s resources allow us to tap our collective pool of knowledge and provide complete end-to-end solutions for our customers. Together, we can do more, faster and better.”
Fujifilm is dedicated to accelerating innovation and services to customers helping advance biological research leading to cellular therapies and drug discovery, by leveraging synergies and strengths between its life science companies.
FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery and cell therapies. The pre-clinical stage company is using its expertise in iPSC technologies to develop a robust pipeline of cell therapeutics candidates. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the company’s inventoried iCell® products that are available in many cell types and sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell services and cell banking. FCDI’s goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world. For more information, please visit: www.FujifilmCDI.com
FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.
FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.